



## Apogee Therapeutics Announces Poster Presentation at the ACAAI 2024 Annual Scientific Meeting

October 16, 2024 11:00 AM EDT

SAN FRANCISCO and WALTHAM, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced an upcoming poster presentation at the American College of Allergy, Asthma & Immunology's (ACAAI) 2024 Annual Scientific Meeting, held in Boston from October 24-28, 2024. The company plans to present data up to 9 months from the ongoing Phase 1 clinical trial of APG777, a novel half-life extended anti-IL-13 antibody for the treatment for atopic dermatitis and other inflammatory diseases.

**Title:** APG777, anti-IL-13 monoclonal antibody, demonstrates extended half-life and sustained inhibition of Type 2 inflammatory biomarkers

**Abstract ID:** R162

**Authors:** Xiu Qin Lim, M.B.B.S., Erica Winter, Pharm.D., Kristine Nograles, M.D., Sai Thankamony, Ph.D., Lukas Dillinger, Ph.D., Carl Dambkowski, M.D.

**Date/Time:** Friday, October 25, 2:00-6:00 p.m. ET

**Location:** Hynes Convention Center – Boston, Hall A

Full session details can be accessed on the [ACAAI website](#). The poster will be available on the [publications page](#) of the Apogee website on October 24.

### About Apogee

Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD and other I&I indications. Apogee's antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company's most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today's standard of care. For more information, please visit <https://apogeetherapeutics.com>.

### Investor Contact:

Noel Kurdi

VP, Investor Relations

Apogee Therapeutics, Inc.

[Noel.Kurdi@apogeetherapeutics.com](mailto:Noel.Kurdi@apogeetherapeutics.com)

### Media Contact:

Dan Budwick

1AB Media

[dan@1abmedia.com](mailto:dan@1abmedia.com)